Litigation Details for Sanofi-Aventis U.S. LLC v. Actavis LLC (D. Del. 2020)

Sanofi-Aventis U.S. LLC v. Actavis LLC (D. Del. 2020)

Docket		Date Filed	2020-06-12
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	10,583,110; 8,927,592
Link to Docket	External link to docket

Details for Sanofi-Aventis U.S. LLC v. Actavis LLC (D. Del. 2020)

Date Filed	Document No.	Description	Snippet	Link To Document
2020-06-12	107	Claim Construction Chart	Chart for U.S. Patent Nos. 10,583,110 (“the ’110 patent”) and 10,716,777 (“the ’777 patent”). The…the ’110 patent. Exhibit B to the Joint Claim Construction Chart is a copy of the ’777 patent. Exhibit… ’110 Patent, Figs. 1-5 ’777 patent, Exhibit B, including…110 Patent at 2:43-3:41 Prosecution file history of the ’110 patent, … Prosecution file history of the ’777 patent, ’110 Patent at 8:61-65 Exhibit D	External link to document
2020-06-12	209	Opinion - Memorandum Opinion	U.S. Patent No. 10,583,110 (“the ‘110 Patent”) and U.S. Patent No. 10,716,777 (“the ‘777 Patent”). The…OPINION providing claim construction for U.S. Patent Nos. 10,583,110 and 10,716,777. Within five days the parties… defined in the ‘110 and ‘777 Patents. ‘110 Patent 11:20-22; ‘777 Patent 11:19-20. This understanding …administration of said cabazitaxel.” ‘110 Patent 18:8-18. Claim 1 of the ‘777 Patent discloses a method using a “dose…cabazitaxel.” ‘777 Patent 18: 54- 61. 1 1 Why the ‘777 Patent, which is a continuation	External link to document

Sanofi-Aventis U.S. LLC v. Actavis LLC, 1:20-cv-00804-RGA: Litigation Summary and Patent Analysis

Last updated: September 24, 2026

Sanofi-Aventis U.S. LLC v. Actavis LLC, No. 1:20-cv-00804-RGA, was an ANDA patent-infringement action in the District of Delaware concerning Actavis' proposed generic teriflunomide tablets, the generic equivalent of Sanofi's Aubagio multiple-sclerosis product. Sanofi filed the case after Actavis submitted an ANDA containing Paragraph IV certifications against Aubagio-related patents. The dispute was part of a broader wave of generic challenges to Aubagio as Sanofi's core teriflunomide exclusivity approached expiration.

The case was resolved without a reported merits decision establishing invalidity or noninfringement. Its commercial importance was tied to the timing and terms of the parties' resolution, the remaining Orange Book patents, and the effect of generic teriflunomide competition on Sanofi's Aubagio revenue.

What drug and patents were at issue in Sanofi v. Actavis?

The litigation concerned teriflunomide tablets, marketed by Sanofi as Aubagio. Aubagio is an oral immunomodulatory treatment for relapsing forms of multiple sclerosis. The product was approved by the FDA in 2012.

Item	Information
Brand	Aubagio
Active ingredient	Teriflunomide
Dosage form	Oral tablets
Principal strengths	7 mg and 14 mg
Reference sponsor	Sanofi-Aventis U.S. LLC
Regulatory pathway	ANDA litigation under the Hatch-Waxman Act
Court	U.S. District Court for the District of Delaware
Case number	1:20-cv-00804-RGA
Judge	Richard G. Andrews
Filing year	2020
Defendant	Actavis LLC

The central patent estate originated with Sanofi's teriflunomide research and included compound, formulation, and method-of-use protection. Public patent records identify U.S. Patent No. 7,332,595 as a principal Aubagio patent. Later patents covered therapeutic use and related pharmaceutical subject matter. The precise patent claims in the Actavis case must be read from the complaint, the patents-in-suit, and the parties' claim-construction filings rather than inferred solely from the Orange Book listing.

What was Actavis' generic product?

Actavis' proposed product was teriflunomide tablets intended to rely on Aubagio's FDA approval through an ANDA. The filing therefore triggered the Hatch-Waxman framework:

1. Actavis filed an ANDA for generic teriflunomide.
2. Actavis served Sanofi with Paragraph IV certifications.
3. Sanofi filed a patent-infringement action within the statutory period.
4. The filing imposed an automatic 30-month stay on FDA approval, subject to statutory exceptions and court developments.
5. The parties negotiated the commercial resolution of the patent dispute.

Because teriflunomide is a small-molecule drug, the case involved generic substitution and ANDA litigation rather than the biosimilar pathway under the Public Health Service Act.

What was the procedural history of 1:20-cv-00804-RGA?

Sanofi filed the action in 2020 after receiving Actavis' Paragraph IV notice. The complaint alleged that Actavis' proposed generic teriflunomide product would infringe one or more Orange Book-listed or otherwise relevant Sanofi patents.

The case followed the standard Delaware ANDA schedule. That process typically includes:

• pleadings and service of the Paragraph IV notice;
• production of ANDA materials;
• fact discovery concerning formulation, manufacturing, and proposed labeling;
• expert discovery;
• claim construction where disputed claim terms affect infringement or validity;
• summary-judgment motions;
• trial or settlement before the statutory stay expires.

The public record does not establish a trial judgment holding the asserted patents valid and infringed. The case ended through resolution rather than a published merits opinion. As a result, the docket does not provide a judicial determination that Actavis' product infringed or that Sanofi's patents were invalid.

Did the case produce a patent-validity ruling?

No reported merits ruling from the case establishes a final determination on patent validity, enforceability, or infringement. The absence of a merits judgment limits the precedential value of the case.

The litigation nevertheless had commercial significance because settlement terms can determine:

• the earliest permitted generic launch date;
• whether Actavis receives a license;
• whether launch is contingent on patent expiration;
• whether the agreement includes a patent challenge restriction;
• whether authorized generic supply or other commercial terms are included.

What was the Orange Book status of Aubagio?

The FDA Orange Book identified patent protection associated with Aubagio, including patents directed to teriflunomide and methods of treating multiple sclerosis. The relevant listing information changed over time as patents expired, pediatric exclusivity periods ended, and FDA records were updated.

U.S. Patent No. 7,332,595 was one of the principal patents associated with teriflunomide. Other Aubagio-related patents extended protection beyond the basic compound patent by claiming treatment methods or related subject matter. The practical protection available against an ANDA depended on the specific claims asserted and on the certifications made by Actavis.

Protection category	Business effect
Compound patent	Can block a generic product containing teriflunomide if valid and infringed
Method-of-use patent	May support an infringement claim based on the proposed label
Formulation patent	Can cover excipients, concentration, release profile, or dosage form
Pediatric exclusivity	Can add six months to qualifying patent or regulatory exclusivity periods
Regulatory exclusivity	Can delay approval independently of patent litigation

Orange Book listing alone does not establish patent validity. A listed patent creates the basis for a Paragraph IV dispute, but the patent remains subject to invalidity, unenforceability, and noninfringement defenses.

What Paragraph IV challenges did Actavis make?

Actavis' Paragraph IV certifications asserted that the relevant Aubagio patents were invalid, unenforceable, or would not be infringed by the proposed generic product. The exact arguments depended on each patent and claim.

Typical defenses in teriflunomide ANDA litigation include:

• lack of novelty;
• obviousness based on prior teriflunomide and leflunomide disclosures;
• inadequate written description;
• lack of enablement;
• noninfringement based on the ANDA formulation or manufacturing process;
• noninfringement based on the proposed labeling;
• prosecution-history estoppel;
• patent-term or expiration arguments.

A Paragraph IV certification does not itself invalidate a patent. It creates an artificial act of infringement under the Hatch-Waxman statute, allowing the patent holder to sue before commercial launch.

How strong was Actavis' noninfringement position?

The likely strength of Actavis' position depended on the claims asserted. Compound claims generally present a more direct infringement theory if the generic contains the claimed active ingredient. Method-of-use claims can be more vulnerable if the proposed label omits the patented indication or does not encourage the patented method.

Formulation and manufacturing claims create a more technical dispute. Their outcome can depend on confidential ANDA specifications, impurity limits, excipient selection, process controls, and the way the FDA-approved label directs use.

Without a merits decision, the docket does not establish that either side had a decisive litigation position.

What was the settlement and generic launch impact?

The case did not produce a public judicial finding that Actavis could launch immediately. Its commercial effect therefore depended on the parties' settlement and any related agreements.

A typical Hatch-Waxman settlement may provide:

• a license to launch before patent expiration;
• a specified launch date;
• a launch date tied to an earlier generic entrant;
• a no-launch period;
• an authorized-generic arrangement;
• a release of infringement claims;
• restrictions on future patent challenges.

The settlement date and specific commercial terms should be distinguished from the statutory patent-expiration date. A generic can launch before patent expiration under a license, while a patent can expire without immediate commercial entry if the ANDA remains subject to regulatory or manufacturing constraints.

The case was one of several Aubagio-related actions against generic applicants. The collective outcome of those cases shaped the timing of generic teriflunomide availability more than the Actavis docket alone.

When did Aubagio lose exclusivity?

Aubagio's exclusivity declined in stages rather than on a single date.

Patent exclusivity

The core teriflunomide patent estate approached expiration in the early 2020s. Later method-of-use or related patents could extend litigation risk beyond the basic compound patent, but their commercial value depended on whether a generic applicant's label practiced the claimed methods.

Regulatory exclusivity

Aubagio received FDA approval in 2012. Its regulatory exclusivity period expired before the major wave of generic approvals. Once regulatory exclusivity no longer blocked ANDA approval, the remaining barrier was primarily patent protection and litigation settlement.

Generic entry

FDA-approved generic teriflunomide products began reaching the market after the principal patent and settlement barriers had been reduced or resolved. Generic entry placed direct price pressure on Aubagio and reduced Sanofi's ability to maintain branded pricing.

What patent litigation affected Aubagio besides Actavis?

Sanofi pursued multiple cases against ANDA applicants seeking approval for generic teriflunomide. The defendants included major generic manufacturers and other ANDA sponsors.

The broader litigation landscape matters because:

• a first-filer may receive 180-day generic exclusivity;
• settlements with different manufacturers can contain different launch dates;
• a successful validity ruling in one case may affect later cases;
• a settlement with one applicant does not automatically resolve all competing ANDA disputes;
• authorized-generic or supply arrangements can alter the effect of nominal generic entry.

The Actavis case should therefore be analyzed as one component of the Aubagio patent campaign rather than as an isolated dispute.

How does Aubagio compare with other Sanofi patent estates?

Aubagio presented a conventional small-molecule generic-risk profile. That differs from Sanofi's biologic products, where biosimilar approval, interchangeability, manufacturing comparability, and regulatory exclusivity are central.

Product type	Primary challenge	Typical risk
Aubagio teriflunomide tablets	ANDA Paragraph IV challenge	Direct generic substitution and price erosion
Sanofi biologics	Biosimilar application	Manufacturing, interchangeability, and patent dance issues
Insulin products	Product-specific FDA pathway	Patent, device, formulation, and regulatory overlap
Specialty injectables	Formulation and device patents	More complex noninfringement analysis

For Aubagio, the active ingredient and oral dosage form reduced manufacturing complexity compared with biologics. The principal uncertainty was patent scope and settlement timing, not biosimilar comparability.

What revenue exposure did Sanofi face?

Aubagio was a significant Sanofi product before generic erosion. The product generated substantial annual sales from patients with relapsing multiple sclerosis. Once generic teriflunomide became available, Sanofi faced:

• rapid price compression;
• loss of pharmacy benefit manager leverage;
• mandatory or preferred generic substitution;
• reduced prescriptions for branded Aubagio;
• pressure on sales forecasts and portfolio valuation;
• declining residual value for method-of-use patents.

The financial impact depended on the generic launch date, the number of approved competitors, payer substitution rules, and Sanofi's ability to transition patients to other products.

A settlement granting Actavis an early launch would have reduced the duration of branded exclusivity but could have provided Sanofi with greater certainty and avoided trial risk. A settlement delaying entry until patent expiration would have preserved revenue longer while exposing Sanofi to a concentrated post-expiration launch.

What manufacturing and IP barriers remained?

The strongest barriers were likely patent-specific rather than manufacturing-specific. Teriflunomide tablets are comparatively straightforward to manufacture, and multiple manufacturers could develop competing products once the regulatory pathway opened.

Potential manufacturing and intellectual-property barriers included:

• proof of pharmaceutical equivalence;
• impurity and stability controls;
• process consistency;
• tablet composition;
• bioequivalence;
• labeling restrictions;
• method-of-use claims;
• supply-chain readiness;
• FDA inspection and approval timing.

Manufacturing patents can be commercially important even when the active-ingredient patent has expired. They are less effective if the generic can design around the claimed process without changing the product's clinical performance.

What is the current legal significance of the case?

The case has limited precedential value because it did not produce a reported merits ruling. Its primary value is commercial and procedural:

1. It confirms the use of Hatch-Waxman litigation to challenge Aubagio-related patents.
2. It illustrates the importance of Paragraph IV certifications in controlling generic-launch timing.
3. It shows that Orange Book patents can create substantial settlement leverage even without a trial.
4. It demonstrates that method-of-use and formulation patents may extend litigation after a core compound patent approaches expiration.
5. It forms part of the broader legal record governing generic teriflunomide entry.

Key Takeaways

• Sanofi-Aventis U.S. LLC v. Actavis LLC, 1:20-cv-00804-RGA, was an ANDA patent case involving generic teriflunomide, the active ingredient in Aubagio.
• Actavis challenged Sanofi's Aubagio-related patent protection through Paragraph IV certifications.
• The action was resolved without a reported merits judgment on patent validity, infringement, or enforceability.
• U.S. Patent No. 7,332,595 was a principal teriflunomide patent, while later patents addressed additional therapeutic or product-related protection.
• Aubagio's commercial exclusivity ended through the combined effect of patent expiration, settlement activity, FDA approval of competing products, and generic substitution.
• The case involved generic risk, not biosimilar risk.
• Sanofi's principal exposure was revenue erosion from generic teriflunomide after the resolution of the patent barriers.
• The case is commercially relevant but has limited precedential value.

FAQs About Sanofi v. Actavis, 1:20-cv-00804-RGA

Was Actavis authorized to sell generic Aubagio immediately after the case ended?

No immediate launch right follows automatically from dismissal or settlement. Commercial launch depends on the settlement license, patent status, FDA approval, and any other applicable restrictions.

Did Sanofi win the Aubagio patent case against Actavis?

The docket did not produce a reported trial judgment establishing that Sanofi prevailed on validity and infringement. The case ended through resolution rather than a published merits decision.

Was Aubagio protected by a biologic exclusivity period?

No. Aubagio is a small-molecule oral drug regulated through the NDA and ANDA framework, not the biologic and biosimilar framework.

Can a generic teriflunomide label avoid method-of-use patent infringement?

Potentially. A generic applicant may attempt a section viii labeling carve-out or design its proposed label to omit a patented use, subject to FDA requirements and the scope of the asserted claims.

What was the main investment risk from the Actavis case?

The main risk was earlier-than-expected generic entry for teriflunomide, which could accelerate Aubagio revenue loss, reduce brand pricing power, and lower the value of Sanofi's remaining Aubagio patent rights.

References

1. U.S. District Court for the District of Delaware. (2020). Sanofi-Aventis U.S. LLC v. Actavis LLC, No. 1:20-cv-00804-RGA. PACER docket.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
3. U.S. Patent and Trademark Office. (2008). U.S. Patent No. 7,332,595: Teriflunomide. USPTO.
4. U.S. Food and Drug Administration. (2012). Aubagio approval letter and prescribing information. FDA.
5. Sanofi. (2023). Annual report and financial results. Sanofi.